- The approval is based on trial results assessing reSET-O in 170 patients receiving either treatment-as-usual (TAU) + standard clinician interactions + buprenorphine or reSET-O + standard clinician interactions + buprenorphine for 12 wks.
- The study demonstrated improved and increase rates of retention time with efficacy results in patients with OUD
- reSET-O is a FDA approved Prescription Digital Therapeutic mobile medical application for 12 weeks, delivering a cognitive behavioral therapy for OUD patients aged ≥18 yrs. In Nov 2018, reSET received FDA approval for Substance Use Disorder (SUD)
Click here to read full press release/ article | Ref: Novartis| Image: Medical Product Outsourcing